Clinical trials: CML (Chronic Myelogenous Leukemia)
Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer.
- Conditions
- Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
- Trial name
- NCT00898079
- Testing
- Cytology Specimen Collection Procedure
- Where
- 192 sites in United States, Australia and 4 more
- Volunteers
- 2,545 people
- Sponsor
- Children's Oncology Group
Chronic Myeloid Leukemia
Nilotinib Plus Pegylated Interferon-α2b in CML
The purpose of this trial is to assess the effect of switching CML patients, who have been treated with imatinib ≥ 2 years and who have stable detectable molecular residual disease between 0.01-1.0% (IS), to the combination of…
- Trial name
- NCT01866553
- Testing
- Nilotinib, Pegylated interferon α-2b
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Chronic Myeloid Leukemia
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
Rationale The pharmacokinetics of imatinib and nilotinib, two BCR/Abl tyrosine-kinase inhibitors (TKI), is variable among patients suffering from chronic myeloid leukemia (CML).
- Trial name
- TIKlet (NCT01860456)
- Testing
- Imatinib/Nilotinib
- Where
- 2 sites in Italy
- Volunteers
- 412 people
- Sponsor
- University of Pisa
Chronic Myeloid Leukemia
LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients
The broad goal of this study is to investigate if differences exist (and in which areas and of what magnitude) in QoL and symptoms of patients with CML being treated with first line therapy with dasatinib versus those receiving…
- Trial name
- QoL-CML0713 (NCT02164903)
- Testing
- QoL Survey Booklet
- Where
- 49 sites in France, Germany and 2 more
- Volunteers
- 323 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Real-Life Database
Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their…
- Trial name
- NCT05963061
- Where
- 14 sites in France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Myeloid Leukemia (CML)
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
A non-randomized, open-label study to investigate the effects of imatinib mesylate on the pharmacokinetics of acetaminophen/paracetamol in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic…
- Trial name
- NCT00428909
- Testing
- Imatinib/Acetaminophen
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive
- Trial name
- NCT00390793
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia, Chronic Phase
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
- Trial name
- AsterA (NCT06368414)
- Testing
- Asciminib
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Korean Society of Hematology
CML (Chronic Myelogenous Leukemia)
A Study for PRO of CML in Real Word
Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians.
- Trial name
- Case-Only (NCT05092048)
- Testing
- questionnaire
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- xuna
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00036738
- Testing
- Cyclosporine, Dasatinib, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloid Leukemia
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
This is a multicentre ambispective cohort study involving French patients who have started or are receiving for less than 6 months a treatment with ponatinib.
- Trial name
- NCT04048564
- Where
- 40 sites in France
- Volunteers
- 120 people
- Sponsor
- Incyte BioSciences France
Leukemia, Lymphoma
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as melphalan and fludarabine, and a monoclonal antibody, such as alemtuzumab, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00027560
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00900068
- Testing
- immunoenzyme technique, laboratory biomarker analysis, medical chart review
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloid Leukemia (CML)
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
This is a multi-center, prospective, single-arm, non-randomized, interventional phase II study of CML patients in first or second chronic phase (i.e. after allogeneic stem cell transplantation) and proven BCR::ABL1 T315I mutation.
- Trial name
- ESTIMATION (NCT07789574)
- Testing
- asciminib 200 mg BID
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Thomas Ernst, PD Dr. med.
Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure.
- Conditions
- Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells, Blasts Under 30 Percent of Peripheral Blood White Cells
- Trial name
- NCT02906696
- Testing
- Bosutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
Nilotinib in PH+, BCR-, ABL+ CML Patients
This study is an open-label, multicentric, phase IIIb study of NILOTINIB administered orally twice daily for 24 months and indefinitely if it is in the interest of the patient.
- Trial name
- CML0811 (NCT01535391)
- Testing
- Nilotinib
- Where
- 34 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
To satisfy a postmarketing requirement, the sponsor has been requested to conduct a Phase 1/Phase 2 single-group clinical study to investigate the pharmacokinetics and preliminary safety and efficacy of omacetaxine following a…
- Trial name
- NCT02078960
- Testing
- Omacetaxine mepesuccinate
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00040846
- Testing
- alemtuzumab, fludarabine phosphate, total-body irradiation
- Where
- 7 sites in United States, Italy
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Phase Chronic Myeloid Leukemia
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML)…
- Trial name
- NCT03045120
- Where
- 24 sites in United States
- Volunteers
- 118 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00816413
- Testing
- cyclosporine, mycophenolate mofetil, pentostatin
- Sponsor
- University of Nebraska
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.